Skip to main content

IP Roundup: Jan 12, 2010


Agilent Technologies has received US Patent No. 7,645,578, "Cleavage of RNA at redundant sites." The patent describes methods for treating samples of RNA. The method includes contacting the sample of RNA with a set of oligodeoxynucleotides to provide a DNA-RNA duplex. The DNA-RNA duplex is then contacted with an enzyme having a DNA:RNA nuclease activity to provide a digested RNA sample. Kits are also described.

Millipore of Billerica, Mass., has received US Patent No. 7,645,586, "Protein isoform discrimination and quantitative measurements thereof." The patent claims methods, reagents, and apparatus for detecting protein isoforms in a sample, including using combinations of capture agents to identify the isoforms to be detected and measured. The method includes fragmenting the target protein isoforms using a mixture of preselected proteases to produce target peptides; contacting the target peptides with immobilized binding agents; contacting the target peptides with detectably labeled second binding agents; and detecting target peptides bound by combinations of the binding agents to indicate unambiguously the presence of the target protein isoforms in the sample.

Bayer has received US Patent No. 7,645,612, "Kit and method for multi-analyte determination." The patent describes a kit for the qualitative and quantitative determination of analytes composed of a sensor platform with an optical thin-film waveguide with a layer; arrays of biological or biochemical or synthetic recognition elements immobilized on the layer; means for laterally resolved referencing of the excitation light intensity available in the measurement areas; and means for the calibration of luminescence generated in the layer as a consequence of the binding of analytes of the specific interaction with one or more analytes.

Luminex Molecular Diagnostics of Toronto has received US Patent No. 7,645,868, "Families of non-cross-hybridizing polynucleotides for use as tags and tag complements, manufacture and use thereof." The patent describes a family of 1,168 24-mer minimally cross-hybridizing nucleotide sequences obtained using a computer algorithm that have desirable hybridization properties for use in nucleic acid detection assays. The sequence set of 1,168 oligonucleotides was partially characterized in hybridization assays, demonstrating the ability of family members to correctly hybridize to their complementary sequences with minimal cross hybridization.

Illumina has received US Patent No. 7,647,186, "Oligonucleotide ordering system." The patent claims a system for ordering oligonucleotides through a network, such as the Internet. The system provides a mechanism for validating the data provided by a customer, and then displaying graphical images to represent any data that has errors. The system can also pool multiple oligonucleotide samples together by providing graphical images representing oligonucleotide containers, and allowing the customer to select the proper containers to pool, according to the patent.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.